Vistagen Therapeutics, Inc. last reported quarterly results on Aug 14, 2026, for Q1 FY2027 (the quarter ended Jun 30, 2026): revenue of $1.5 million (+504.9% year over year) and diluted EPS of -$0.30. It usually reports 38–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q2 FY2027, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 14, 2026
45 days after quarter end
|
Q1 FY2027
ended Jun 30, 2026
|
1
+504.9%
|
-13
+13.7%
|
-0.30
+36.2%
|
|
Feb 12, 2026
43 days after quarter end
|
Q3 FY2026
ended Dec 31, 2025
|
0
+29.5%
|
-19
-34.1%
|
-0.45
+2.2%
|
|
Nov 13, 2025
44 days after quarter end
|
Q2 FY2026
ended Sep 30, 2025
|
0
+41.0%
|
-19
-49.8%
|
-0.54
-28.6%
|
|
Aug 7, 2025
38 days after quarter end
|
Q1 FY2026
ended Jun 30, 2025
|
0
+190.5%
|
-15
-40.6%
|
-0.47
-34.3%
|
|
Feb 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Dec 31, 2024
|
0
-43.1%
|
-14
-121.9%
|
-0.46
|
|
Nov 7, 2024
38 days after quarter end
|
Q2 FY2025
ended Sep 30, 2024
|
0
-34.2%
|
-13
-96.7%
|
-0.42
|
|
Aug 13, 2024
44 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Jun 11, 2024
72 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTGN (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd. (until Jun 8, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.